Publications

Reach out for information on innovative treatments and collaborations.

A healthcare professional wearing a surgical mask, disposable gloves, and a hairnet closely examines a vial of liquid. The background is blurred with blue and white tones, suggesting a clinical environment.

97

6

Research Publications

Clinical Partnerships

Contact us for more information on our cutting-edge treatments and exciting collaboration opportunities. We're eager to share how our innovative solutions can make a difference and explore potential partnerships to advance our shared goals.

A Few Select Publications

A ROS-Activatable Agent Elicits Homologous Recombination DNA Repair and Synergizes with Pathway Compounds

Biologically relevant oxidants cause bound proteins to readily oxidatively cross-link at Guanine

Design of a hydrogen peroxide-activatable agent that specifically targets cancer cells

Identification of selenium-containing proteins in HEK 293 kidney cel using multiple chromatographies, LC–ICPMS and nano-LC–ESIMS

Novel Oxidatively Activated Agents Modify DNA and are Enhanced by Ercc1 Silencing

Novel ROS-activated agents utilize a tethered amine to selectively target acute myeloid leukemia

Oxidatively Activated DNA-Modifying Agents for Selective Cytotoxicity

Phosphoinositide 3-Kinase (PI3K) Reactive Oxygen Species (ROS)-Activated Prodrug in Combination with Anthracycline Impairs PI3K Signaling, Increases DNA Damage Response and Reduces Breast Cancer Cell Growth

Ruthenium Complexes are pH-Activated Metallo Prodrugs (pHAMPs) with Light-Triggered Selective Toxicity Toward Cancer Cells

Self-Cyclizing Antioxidants to Prevent DNA Damage Caused by Hydroxyl Radical

Contact Us

Partnerships@rytolscience.com

Rytol Bioscience

Leading biopharmaceutical company for rare CNS diseases.

Research

contact@rytolscience.com